Caccaro R, Angriman I, D’Incà R. Relevance of fecal calprotectin and lactoferrin in the post-operative management of inflammatory bowel diseases. World J Gastrointest Surg 2016; 8(3): 193-201 [PMID: 27022446 DOI: 10.4240/wjgs.v8.i3.193]
Corresponding Author of This Article
Roberta Caccaro, MD, PhD, Department of Surgery, Oncology and Gastroenterology, Gastroenterology Section, University Hospital of Padua, via Giustiniani 2, 35128 Padua, Italy. roberta.caccaro@gmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Surg. Mar 27, 2016; 8(3): 193-201 Published online Mar 27, 2016. doi: 10.4240/wjgs.v8.i3.193
Relevance of fecal calprotectin and lactoferrin in the post-operative management of inflammatory bowel diseases
Roberta Caccaro, Imerio Angriman, Renata D’Incà
Roberta Caccaro, Renata D’Incà, Department of Surgery, Oncology and Gastroenterology, Gastroenterology Section, University Hospital of Padua, 35128 Padua, Italy
Imerio Angriman, Department of Surgery, Oncology and Gastroenterology, Surgery Section, University Hospital of Padua, 35128 Padua, Italy
Author contributions: Caccaro R, Angriman I and D’Incà R all contributed to this paper and fulfill all the criteria for authorship.
Conflict-of-interest statement: None to declare.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Roberta Caccaro, MD, PhD, Department of Surgery, Oncology and Gastroenterology, Gastroenterology Section, University Hospital of Padua, via Giustiniani 2, 35128 Padua, Italy. roberta.caccaro@gmail.com
Telephone: +39-049-8212890 Fax: +39-049-8760820
Received: September 15, 2015 Peer-review started: September 17, 2015 First decision: October 30, 2015 Revised: December 17, 2015 Accepted: January 8, 2016 Article in press: January 11, 2016 Published online: March 27, 2016
Core Tip
Core tip: Inflammatory bowel diseases (IBDs) are chronic conditions, requiring life-long therapy and monitoring. Surgery is not curative and the disease might recur after operation as post-operative recurrence in Crohn’s disease patients and pouchitis in ulcerative colitis patients. In both cases, endoscopy with histology is the gold standard procedure to assess disease activity. Non-invasive markers of intestinal inflammation, such as fecal calprotectin and lactoferrin, might be useful in the post-operative management of IBD patients, in order to identify individuals requiring endoscopy, so that they can avoid unnecessary invasive investigations. This paper reviews the current knowledge on the use of fecal markers in this specific setting.
